Additionally, it has been noted in preclinical studies that selenium compounds, which are regarded to be less expensive than anti-TGF-β1 drugs, are safe and nontoxic when administered in dosages that show anti-tumor efficacy [52,53]. This evidence concerns the gene TGFB1 and neoplasm.